Dear Doctor Letter (Rote-Hand-Brief) on combined hormonal contraceptives, including information material: Risk of venous thromboembolic events
2014.02.03
Active substance: gestagen components: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin, norgestimat
In coordination with the European Medicines Agency and the Federal Institute for Drugs and Medical Devices, the pharmaceutical manufacturers concerned are circulating information on new aspects of the risk of blood clots (venous thromboembolic events, VTE) associated with the use of combined hormonal contraceptives depending on the gestagen component.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN